论文部分内容阅读
目的总结分析老年2型糖尿病患者治疗中门冬胰岛素30和格列吡嗪控释片的临床应用效果。方法以我院2015年2月至2016年5月期间接收的60例老年2型糖尿病患者为研究对象,所有患者的糖化血红蛋白浓度在9.0%~11.0%,随机分为观察组(30例)和对照组(30例),对照组采用格列吡嗪控释片,观察组采用门冬胰岛素30,回顾分析两组患者治疗的相关资料。结果在治疗后的空腹血糖、餐后2h血糖以及糖化血红蛋白指标方面,观察组优于对照组(P<0.05),具有统计学意义。结论对于糖化血红蛋白浓度在9.0%~11.0%的老年2型糖尿病患者,使用门冬胰岛素30治疗相对于格列吡嗪控释片,效果显著,可明显降低患者血糖,值得临床推广应用。
Objective To summarize the clinical effects of aspart insulin 30 and glipizide in elderly patients with type 2 diabetes mellitus. Methods Sixty elderly patients with type 2 diabetes mellitus received from February 2015 to May 2016 in our hospital were enrolled. All patients had a HbA1c concentration of 9.0% ~ 11.0%, and were randomly divided into observation group (30 cases) and control group The control group (30 cases), the control group with glipizide controlled release tablets, the observation group using insulin aspart 30, retrospective analysis of the two groups of patients with relevant data. Results In the fasting blood glucose, 2h postprandial blood glucose and glycosylated hemoglobin, the observation group was superior to the control group (P <0.05), with statistical significance. Conclusion Asystatin 30 is superior to glipizide in patients with type 2 diabetes mellitus with glycosylated hemoglobin (HbA1c) of 9.0% ~ 11.0%. The effect is significant, which can significantly reduce the blood glucose of patients. It is worthy of clinical application.